Compare AbCellera Biologics Inc (ABCL) vs AMETEK, Inc. (AME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs AMETEK, Inc. — how do they compare? AbCellera Biologics Inc trades at $9.33 (market cap $2.85B), while AMETEK, Inc. trades at $255.78 (market cap $57.98B). The key difference: AMETEK, Inc. is far larger — about 20.3× AbCellera Biologics Inc's market cap, and AMETEK, Inc. pays a 0.54% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | AME | |
|---|---|---|
Market Cap | $2.85B | $57.98B |
Sector | Health | Industrials |
52-Week High | $9.34 | $254.76 |
52-Week Low | $2.78 | $179.28 |
Enterprise Value | $2.45B | $59.52B |
Dividend Yield | — | 0.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
AME trades at $253.66, up 0.91% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $2.09 vs. $1.99 expected), revenue growth to $7.40B in 2025, and robust profitability (20.04% net margin). Recent news highlights momentum in 3D printing and electronics testing sectors. Analyst consensus is strongly bullish with a $281.86 price target.
Outlook remains positive given earnings momentum and raised guidance, but risks include elevated valuation (P/E 37.08) and RSI overbought signals. Institutional support is strong with no sell ratings. The stock offers growth potential but requires monitoring of valuation metrics amid current levels near resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
